Screener
Candel Therapeutics, Inc. CADL Income Statement
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| $19.8M+183% | $9.84M+145% | $11.03M+129% | $8.46M+56.2% | $6.99M+40.4% | ||
| $6.95M+65.9% | $6.44M+56.6% | $4.72M+42.1% | $4.75M+42.1% | $4.19M+16.5% | ||
| $26.75M+139% | $16.28M+100% | $15.75M+93.5% | $13.21M+50.8% | $11.18M+30.4% | ||
| -$26.75M-139% | -$16.28M-100% | -$15.75M-93.5% | -$13.21M-50.8% | -$11.18M-30.4% | ||
| $1.58M+567% | $1.56M+411% | $1.42M+263% | $161K-66.9% | $236K-58.4% | ||
| -$12.16M-291% | $7.42M-52.1% | —— | $1.94M+203% | $6.38M+147% | ||
| -$38.91M-711% | -$8.86M-220% | -$29.5M-110% | -$11.27M-5.9% | -$4.8M+78.4% | ||
| -$0.52-478% | -$0.14-208% | -$0.55-41.0% | -$0.21+36.4% | -$0.09+87.8% | ||
| -$26.55M-142% | -$16.14M-105% | -$15.59M-97.4% | -$13.01M-52.0% | -$10.98M-31.1% | ||
| -$26.75M-139% | -$16.28M-100% | -$15.75M-93.5% | -$13.21M-50.8% | -$11.18M-30.4% |
FAQ
- Is Candel Therapeutics, Inc. profitable?
- Candel Therapeutics, Inc. is not currently profitable: it reported a net loss of $88.5M over the trailing twelve months, a -15156.5% net margin.
- What is Candel Therapeutics, Inc.'s earnings per share?
- Candel Therapeutics, Inc.'s diluted EPS over the trailing twelve months is $-1.42.
- Where does Candel Therapeutics, Inc.'s income statement data come from?
- Every line is extracted from Candel Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.